Prostate and other male cancers:
Indications for: FIRMAGON
Advanced prostate cancer.
Adult Dosage:
Give by SC inj in abdomen once every 28 days; avoid waist and rib areas. Two 120mg injections once, then one 80mg inj once every 28 days.
Children Dosage:
Not established.
FIRMAGON Warnings/Precautions:
Congenital long QT syndrome. CHF. Correct electrolyte abnormalities. Monitor electrolytes and ECG periodically. Monitor serum PSA. Discontinue if serious hypersensitivity reaction occurs; do not rechallenge. Moderate or severe renal impairment (CrCl <50mL/min). Severe hepatic impairment. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.
FIRMAGON Classification:
GnRH antagonist.
FIRMAGON Interactions:
Caution with concomitant drugs known to prolong the QT interval.
Adverse Reactions:
Inj site reactions (eg, pain, erythema, swelling, induration), hot flashes, increased weight, fatigue, increased transaminases, increased gamma-glutamyltransferase; QT prolongation.
How Supplied:
Treatment Initiation pack (120mg/vial)—2 (w. supplies); Treatment Maintenance pack (80mg/vial)—1 (w. supplies)
